A TRIAL OF MYCOPHENOLATE MOFETIL IN MYASTHENIA GRAVIS

霉酚酸酯治疗重症肌无力的试验

• 批准号: 7374580
• 负责人: JOHN C KISSEL
• 金额: $ 0.41万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374580
• 关键词: TRIAL; MYCOPHENOLATE; MOFETIL; MYASTHENIA; GRAVIS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this study is to test the hypothesis that mycophenolate mofetil (2.5 g/d) in combination with prednisone (20 mg/d) provides better control of signs and symptoms than prednisone alone in the initial management of myasthenia gravis (MG). A 6 month open-label extension will supply further information about the safety and tolerability of MM at doses ranging from 2.5-3 g/d, and will give some preliminary information about the frequency with which prednisone can be tapered or even discontinued in patients maintained on MM.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是检验以下假设：在重症肌无力（MG）的初始治疗中，吗替麦考酚酯（2.5 g/d）联合泼尼松（20 mg/d）比单用泼尼松更能控制体征和症状。6个月的开放标签扩展将提供关于剂量范围为2.5-3 g/d的MM的安全性和耐受性的进一步信息，并将提供关于维持MM的患者中泼尼松可以逐渐减少甚至停用的频率的一些初步信息。